FDA clears Reponse Biomedical's respiratory syncytial virus test
This article was originally published in Clinica
The US FDA has granted 510(k) clearance for Response Biomedical's respiratory syncytial virus (RSV) test. It will be marketed and sold by 3M Health Care as the 3M Rapid Detection RSV Test, and runs on Response's RAMP 200 Reader and 3M's Rapid Detection Reader.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.